Efficacy and safety of hydroxychloroquine for treatment of mild SARS ‐CoV‐2 infection and prevention of COVID‐19 severity in pregnant and postpartum women: A randomized, double‐blind, placebo‐controlled trial

ConclusionsHCQ was found to be safe in pregnant and postpartum women with asymptomatic or mild SARS-CoV-2 infection. Although the prevalence of infection was decreased in the HCQ group, the statistical power was insufficient to confirm the potential beneficial effect of HCQ for COVID-19 treatment.

Source: Acta Obstetricia et Gynecologica Scandinavica - February 15, 2024 Category: OBGYN Authors: Raquel Gonz ález, Anna Goncé, Mª. del Mar Gil, Edurne Mazarico, Elena Ferriols‐Pérez, Paloma Toro, Elisa Llurba, Elisa Saéz, Miguel Ángel Rodríguez‐Zambrano, Laura García‐Otero, Marta López, Belén Santacruz, Mª. Ángeles Romá Tags: ORIGINAL RESEARCH ARTICLE Source Type: research